Share on Pinterest
Share with your friends


Cost of healthcare in the U.S.

Patients, shareholders take aim at Vertex

Bad NewsKEY TAKEAWAY: Vertex, who is based in downtown Boston, got the kind of headlines that pharma has been trying to avoid.  Three stories, talk about the high price of their new CF drug and the urges shareholders to reject compensation packages for senior executives.

Continue reading »

The real faces of high drug costs

UnknownKEY TAKEAWAY: Biopharma can’t just read about high drug prices in media stories, employees need to get out and listen to patients talk about how it’s affecting their treatment choices and limiting the quality of life THEY want. Continue reading »

False promise of helping patients

npr_drug_inflation_wide-899d7bf8e68346556a3f1ca3fe3a96acbb87de01-s1400-c85KEY TAKEAWAY: If employees of Biopharma companies really want to help patients they can do so by ensuring that everyone who needs their drugs gets them regardless of cost, not by riding in a bicycle event. Continue reading »

On high drug prices…

imagesKEY TAKEAWAY: A report released this week during the largest gathering of biotechnology executives in the world found that pharmaceutical companies are more worried than they were a year ago about their ability to prevail in drug price negotiations. If the M&A frenzy among insurers continues drug companies could find out just how bad a strategy of high drug prices really is. Continue reading »

Prescription drug costs soaring

screenshot_27910 selected new medications are likely to result in medication costs to the government of $49.3 billion over a 10-year period, including: $31.3 billion in Medicare spend; $15.8 billion in state and federal Medicaid spend; and $2.1 billion as a result of subsidies provided through exchange plans. Continue reading »

Patients get caught in the middle of pricing

UnknowninsurerKEY TAKEAWAY: DTC marketing is meant to drive new Rx’s but insurers are having a bigger say about which drugs patients get.  Can the drug industry make peace with insurers or is it going to be a battle of war between profits, Wall Street and patients. Continue reading »